Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

thinkemotive

- PMLiVE

UK study reveals Omicron variant ‘substantially less likely’ to cause long Covid

The new study by King’s College London found that the odds of experiencing long COVID were between 20-50% less during the Omicron period versus the Delta period

Genesis Research & MAT logo

Genesis Research Acquires Market Access Transformation

Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has entered into a definitive agreement to acquire Market Access Transformation (“MAT”),...

Genesis Research Group

Communique Award Bedrock Healthcare Communications

Bedrock’s Accelerated Virtual Consensus Programme for Merck wins at Communiqué Awards

The award recognises outstanding achievement in flexing thinking and processes to ensure success.

Bedrock Healthcare Communications

ISPOR 2022: a retrospective

Genesis Research Group

Genesis Research – an introduction

Genesis Research Group

- PMLiVE

Novo Nordisk announces positive phase 3 results for haemophilia treatment

Haemophilia affects around 1,125,000 people globally

- PMLiVE

Sanofi and Sobi announce positive phase 3 trial results for severe haemophilia A

Results from the study showed once-weekly efanesoctocog alfa doses provided ‘clinically meaningful’ bleed protection for patients with severe haemophilia A

Ensuring fit-for-purpose real-world data to generate real-world evidence with Susan Oliveria

Genesis Research Group

Genesis Research at the World EPA Congress 2022

Genesis Research Group

- PMLiVE

GSK creates new consumer healthcare business, Haleon

Haleon, whose brand portfolio will include Sensodyne toothpaste and Panadol painkillers, is the combination of the consumer health businesses of GSK and Pfizer

- PMLiVE

Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment

The treatment will be available on the NHS as an adjuvant treatment for those at high-risk of recurrence

- PMLiVE

Celebrating the 2022 Communiqué Awards

The Awards, held at the London Grosvenor House Hotel, recognise excellence in medical affairs and healthcare communications

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links